Abivax Announces Launch of Public Offering

Core Viewpoint - Abivax SA has announced the launch of a public offering of approximately $400 million, aimed at funding its clinical development and operational needs [1][10]. Group 1: Offering Details - The public offering will consist of American Depositary Shares (ADSs), each representing one ordinary share of the company, with a nominal value of €0.01 per share [1]. - The company plans to grant underwriters a 30-day option to purchase additional ADSs, up to 15% of the total number proposed to be sold [1]. - The offering price will be determined through a book-building process, and the final amount and terms will be announced after pricing [4][7]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to be allocated as follows: approximately 23% for the development of obefazimod for Ulcerative Colitis, approximately 5% for Crohn's Disease, and about 72% for working capital and general corporate purposes [10][14]. Group 3: Company Background - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases [18]. - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [18]. Group 4: Financial Position - As of June 30, 2025, the company had cash and cash equivalents of $71.4 million, which is expected to finance its operating cash flow requirements into the fourth quarter of 2025 [9].